The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Irinotecan, temozolomide and naxitamab plus GM-CSF (HITS) and naxitamab plus GM-CSF and ifosfamide, carboplatin, etoposide (NICE) for patients with relapsed or refractory high-risk neuroblastoma: A single center, open-label phase 2 clinical trial.
 
Jaume Mora
Consulting or Advisory Role - Bristol Meyers; Ymabs Therapeutics Inc
Research Funding - Roche/Genentech (Inst)
 
Sara Perez-Jaume
No Relationships to Disclose
 
Amalia Varo
No Relationships to Disclose
 
Margarida Simao
No Relationships to Disclose
 
Alicia Castaneda Heredia
No Relationships to Disclose
 
Saray Chamorro
No Relationships to Disclose
 
Juan Pablo Muñoz
No Relationships to Disclose
 
Maite Gorostegui
No Relationships to Disclose
 
Sandra Lopez
No Relationships to Disclose
 
Cristina Larrosa
No Relationships to Disclose